Cargando…

Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma

BACKGROUND: Although many prognostic single-gene (SG) lists have been identified in cancer research, application of these features is hampered due to poor robustness and performance on independent datasets. Pathway-based approaches have thus emerged which embed biological knowledge to yield reproduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fa, Botao, Luo, Chengwen, Tang, Zhou, Yan, Yuting, Zhang, Yue, Yu, Zhangsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606892/
https://www.ncbi.nlm.nih.gov/pubmed/31101593
http://dx.doi.org/10.1016/j.ebiom.2019.05.010
_version_ 1783431985538007040
author Fa, Botao
Luo, Chengwen
Tang, Zhou
Yan, Yuting
Zhang, Yue
Yu, Zhangsheng
author_facet Fa, Botao
Luo, Chengwen
Tang, Zhou
Yan, Yuting
Zhang, Yue
Yu, Zhangsheng
author_sort Fa, Botao
collection PubMed
description BACKGROUND: Although many prognostic single-gene (SG) lists have been identified in cancer research, application of these features is hampered due to poor robustness and performance on independent datasets. Pathway-based approaches have thus emerged which embed biological knowledge to yield reproducible features. METHODS: Pathifier estimates pathways deregulation score (PDS) to represent the extent of pathway deregulation based on expression data, and most of its applications treat pathways as independent without addressing the effect of gene overlap between pathway pairs which we refer to as crosstalk. Here, we propose a novel procedure based on Pathifier methodology, which for the first time has been utilized with crosstalk accommodated to identify disease-specific features to predict prognosis in patients with hepatocellular carcinoma (HCC). FINDINGS: With the cohort (N = 355) of HCC patients from The Cancer Genome Atlas (TCGA), cross validation (CV) revealed that PDSs identified were more robust and accurate than the SG features by deep learning (DL)-based approach. When validated on external HCC datasets, these features outperformed the SGs consistently. INTERPRETATION: On average, we provide 10.2% improvement of prediction accuracy. Importantly, governing genes in these features provide valuable insight into the cancer hallmarks of HCC. We develop an R package PATHcrosstalk (available from GitHub https://github.com/fabotao/PATHcrosstalk) with which users can discover pathways of interest with crosstalk effect considered.
format Online
Article
Text
id pubmed-6606892
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-66068922019-07-15 Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma Fa, Botao Luo, Chengwen Tang, Zhou Yan, Yuting Zhang, Yue Yu, Zhangsheng EBioMedicine Research paper BACKGROUND: Although many prognostic single-gene (SG) lists have been identified in cancer research, application of these features is hampered due to poor robustness and performance on independent datasets. Pathway-based approaches have thus emerged which embed biological knowledge to yield reproducible features. METHODS: Pathifier estimates pathways deregulation score (PDS) to represent the extent of pathway deregulation based on expression data, and most of its applications treat pathways as independent without addressing the effect of gene overlap between pathway pairs which we refer to as crosstalk. Here, we propose a novel procedure based on Pathifier methodology, which for the first time has been utilized with crosstalk accommodated to identify disease-specific features to predict prognosis in patients with hepatocellular carcinoma (HCC). FINDINGS: With the cohort (N = 355) of HCC patients from The Cancer Genome Atlas (TCGA), cross validation (CV) revealed that PDSs identified were more robust and accurate than the SG features by deep learning (DL)-based approach. When validated on external HCC datasets, these features outperformed the SGs consistently. INTERPRETATION: On average, we provide 10.2% improvement of prediction accuracy. Importantly, governing genes in these features provide valuable insight into the cancer hallmarks of HCC. We develop an R package PATHcrosstalk (available from GitHub https://github.com/fabotao/PATHcrosstalk) with which users can discover pathways of interest with crosstalk effect considered. Elsevier 2019-05-14 /pmc/articles/PMC6606892/ /pubmed/31101593 http://dx.doi.org/10.1016/j.ebiom.2019.05.010 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research paper
Fa, Botao
Luo, Chengwen
Tang, Zhou
Yan, Yuting
Zhang, Yue
Yu, Zhangsheng
Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma
title Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma
title_full Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma
title_fullStr Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma
title_full_unstemmed Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma
title_short Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma
title_sort pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma
topic Research paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606892/
https://www.ncbi.nlm.nih.gov/pubmed/31101593
http://dx.doi.org/10.1016/j.ebiom.2019.05.010
work_keys_str_mv AT fabotao pathwaybasedbiomarkeridentificationwithcrosstalkanalysisforrobustprognosispredictioninhepatocellularcarcinoma
AT luochengwen pathwaybasedbiomarkeridentificationwithcrosstalkanalysisforrobustprognosispredictioninhepatocellularcarcinoma
AT tangzhou pathwaybasedbiomarkeridentificationwithcrosstalkanalysisforrobustprognosispredictioninhepatocellularcarcinoma
AT yanyuting pathwaybasedbiomarkeridentificationwithcrosstalkanalysisforrobustprognosispredictioninhepatocellularcarcinoma
AT zhangyue pathwaybasedbiomarkeridentificationwithcrosstalkanalysisforrobustprognosispredictioninhepatocellularcarcinoma
AT yuzhangsheng pathwaybasedbiomarkeridentificationwithcrosstalkanalysisforrobustprognosispredictioninhepatocellularcarcinoma